Product Description: Bedaquiline (TMC207) is a diarylquinoline agent and inhibits Mycobacterium tuberculosis (Mtb) F1FO-ATP synthase through targeting of both the c- and the ε-subunit[1]. Bedaquiline has uncoupler activity. Bedaquiline is used for the multi-agent resistant tuberculosis[2].
Applications: COVID-19-immunoregulation
Formula: C32H31BrN2O2
Citations: ACS Chem Biol. 2021 Dec 15./ACS Infect Dis. 2020 Dec 15./ACS Infect Dis. 2024 Jan 18./Advanced Biochemistry, University of Madras, American.2019, Jan/Antimicrob Agents Chemother. 2019 Sep 23;63(10):e01191-19./Antimicrob Agents Chemother. 2020 Jan 27;64(2):e01540-19./Antimicrob Agents Chemother. 2020 Mar 24;64(4):e02404-19./Antimicrob Agents Chemother. 2021 Jan 25;AAC.01445-20./Antimicrob Agents Chemother. 2021 Jun 21;AAC0095621./Antimicrob Agents Chemother. 2023 Jan 23;e0145922./Antimicrob Agents Chemother. 2024 Oct 29:e0094524./Antimicrob Agents Chemother. 2024 Oct 29:e0105124./bioRxiv. 2024 Oct 30:2024.10.30.620736./bioRxiv. 2025 February 06./Cell. 2023 May 11;186(10):2176-2192.e22./Commun Biol. 2025 Feb 6;8(1):187./Dis Model Mech. 2021 Oct 13;dmm.049145./Eur J Med Chem. 6 August 2022, 114639./Front Cell Infect Microbiol. 2016 Nov 8;6:145. eCollection 2016./Front Microbiol. 2018 Aug 15;9:1898. /Front Microbiol. 2021 Feb 25;12:647611./Int J Pharm. 2024 Feb 21:653:123920./J Biol Chem. 2024 Jan 2:105618./J Pharm Biomed Anal. 2023 Oct 25, 235, 115658./Mbio. 2021 Jun 1;e0108821./Microbiol Spectr. 2021 Jun 16;e0004521./Microbiol Spectr. 2023 Nov 20:e0228223./Nanomedicine. 2025 Mar 18:1-13./Nat Commun. 2021 Jun 21;12(1):3816./Pharmaceuticals. 2023 Sep 15, 16(9), 1309./Research Square Preprint. 2021 Nov./Research Square Preprint. 2022 Feb./Research Square Preprint. 2023 May 2./SLAS Discov. 2020 Sep;25(8):895-905./University of Manitoba. Department of Medical Microbiology and Infectious Diseases. 2022 Jan./Vet Res. 2023 Dec 19;54(1):123./Zoonoses. 2023 Feb 2./ACS Infect Dis. 2024 Aug 13./Università Vita-Salute San Raffaele. 2022 Apr 08. 34.
References: [1]Jang JC, et al. Bedaquiline susceptibility test for totally drug-resistant tuberculosis Mycobacterium tuberculosis. J Microbiol. 2017 Apr 20./[2]Pang Y, et al. In Vitro Activity of Bedaquiline against Nontuberculous Mycobacteria in China. Antimicrob Agents Chemother. 2017 Apr 24;61(5)./[3]Chahine EB, et al. Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis. Ann Pharmacother. 2014 Jan;48(1):107-15./[4]Sarathy JP, et al. TBAJ-876 displays Bedaquiline-like mycobactericidal potency without retaining the parental drug's uncoupler activity. Antimicrob Agents Chemother. 2019 Nov 11.
CAS Number: 843663-66-1
Molecular Weight: 555.50
Compound Purity: 99.98
Research Area: Infection
Solubility: DMSO : 12.5 mg/mL (ultrasonic;warming;heat to 60°C)
Target: Antibiotic;Bacterial
Deutsch
English
